These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 31751766)

  • 1. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
    Massé A; Roulin L; Pasanisi J; Penneroux J; Gachet S; Delord M; Ali A; Alberdi A; Berrou J; Passet M; Hernandez L; Quentin S; Gardin C; Raffoux E; Adès L; Braun T; Soulier J; Clappier E; Dombret H; Puissant A; Itzykson R
    Leuk Res; 2019 Dec; 87():106269. PubMed ID: 31751766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
    [No Abstract]   [Full Text] [Related]  

  • 4. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
    Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN
    Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished AHR Signaling Drives Human Acute Myeloid Leukemia Stem Cell Maintenance.
    Ly M; Rentas S; Vujovic A; Wong N; Moreira S; Xu J; Holzapfel N; Bhatia S; Tran D; Minden MD; Draper JS; Hope KJ
    Cancer Res; 2019 Nov; 79(22):5799-5811. PubMed ID: 31519687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
    Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
    Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
    Kikushige Y; Akashi K
    Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.
    Kikushige Y; Miyamoto T
    Oncology; 2015; 89 Suppl 1():28-32. PubMed ID: 26551150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 17-gene stemness score for rapid determination of risk in acute leukaemia.
    Ng SW; Mitchell A; Kennedy JA; Chen WC; McLeod J; Ibrahimova N; Arruda A; Popescu A; Gupta V; Schimmer AD; Schuh AC; Yee KW; Bullinger L; Herold T; Görlich D; Büchner T; Hiddemann W; Berdel WE; Wörmann B; Cheok M; Preudhomme C; Dombret H; Metzeler K; Buske C; Löwenberg B; Valk PJ; Zandstra PW; Minden MD; Dick JE; Wang JC
    Nature; 2016 Dec; 540(7633):433-437. PubMed ID: 27926740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.
    Hoang VT; Zepeda-Moreno A; Ho AD
    Biotechnol J; 2012 Jun; 7(6):779-88. PubMed ID: 22588704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells.
    Larrue C; Guiraud N; Mouchel PL; Dubois M; Farge T; Gotanègre M; Bosc C; Saland E; Nicolau-Travers ML; Sabatier M; Serhan N; Sahal A; Boet E; Mouche S; Heydt Q; Aroua N; Stuani L; Kaoma T; Angenendt L; Mikesch JH; Schliemann C; Vergez F; Tamburini J; Récher C; Sarry JE
    Nat Commun; 2021 Jan; 12(1):422. PubMed ID: 33462236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
    Bernasconi P; Farina M; Boni M; Dambruoso I; Calvello C
    Am J Hematol; 2016 May; 91(5):507-17. PubMed ID: 26822317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
    Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
    Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.